Carisma Therapeutics, Inc. CARM

CARM Company Overview

Carisma Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing engineered cell therapies for the treatment of cancer and other serious diseases. The company operates within the biotechnology and cell therapy industries, with a primary emphasis on macrophage-based immunotherapies. Its core innovation centers on chimeric antigen receptor macrophages (CAR-M), a novel approach designed to overcome limitations of existing CAR-T and antibody-based therapies, particularly in solid tumors.

Founded in 2016 as a spinout from the University of Pennsylvania, Carisma was built on academic research demonstrating the potential of engineered macrophages to both directly phagocytose tumor cells and reshape the tumor microenvironment. The company became publicly traded in 2022 following its merger with a special purpose acquisition company, marking its transition to a publicly listed clinical-stage enterprise focused on advancing first-in-class cell therapy platforms.